Table 3.

Cancer mortality and incidence risks, SAGhE cohort, for patients in whom a non-cancer diagnosis led to GH treatment

	Initial diagnosis isolated growth failure				Initial diagnosis non-cancer, non-isolated growth failure
Outcome (cancer site)	Cancer mortality		Cancer incidence		Cancer mortality		Cancer incidence
	n	SMR (95% CI)	n	SIR (95% CI)	n	SMR (95% CI)	n	SIR (95% CI)
Colon and rectum	0	0.0 (0.0-12.1)	0	0.0 (0.0-5.2)	1	5.7 (0.1-31.8)	2	2.7 (0.7-10.9)
Bone	3	3.1 (1.0-9.6)	1	1.4 (0.0-8.0)	1	1.8 (0.1-10.1)	3	4.1 (1.3-12.6)a
Melanoma	1	2.6 (0.1-14.5)	3	1.5 (0.5-4.5)	0	0.0 (0.0-16.7)	4	1.5 (0.6-4.0)
Soft tissue	0	0.0 (0.0-8.2)	0	0.0 (0.0-6.0)	0	0.0 (0.0-12.7)	2	3.1 (0.8-12.6)
Cervix	0	0.0 (0.0-64.4)	7	1.1 (0.5-2.4)	0	0.0 (0.0-33.4)	8	0.8 (0.4-1.6)
Testis	0	0.0 (0.0-19.7)	3	1.0 (0.3-3.0)	0	0.0 (0.0-62.3)	1	0.5 (0.0-3.0)
Bladder	0	0.0 (0.0-83.4)	1	8.9 (0.2-49.4)	1	31.0 (0.8-172.9)	2	27.8 (7.0-111.3)b
CNS	0	0.0 (0.0-2.0)	3	1.6 (0.5-4.8)	3	2.6 (0.8-8.0)	3	1.6 (0.5-5.1)
Thyroid	0	0.0 (0.0-371.7)	0	0.0 (0.0-5.5)	0	0.0 (0.0-578.6)	2	2.0 (0.5-7.8)
Hodgkin lymphoma	0	0.0 (0.0-11.5)	3	1.7 (0.6-5.4)	0	0.0 (0.0-20.3)	4	2.0 (0.8-5.4)
NHL	0	0.0 (0.0-5.5)	0	0.0 (0.0-3.9)	0	0.0 (0.0-10.5)	2	2.2 (0.6-8.8)
Leukaemia	2	0.8 (0.2-3.4)	1	0.8 (0.0-4.2)	2	1.5 (0.4-6.1)	2	1.5 (0.4-5.9)
All sites except non-melanoma skin cancer	8	0.8 (0.4-1.6)	23	1.0 (0.6-1.4)	13	2.2 (1.3-3.7)a	42	1.4 (1.1-1.9)a

SMR = Standardised mortality ratio; SIR = Standardised incidence ratio; CI = Confidence interval

^ap<0.05

^bp<0.01